Sort   by:  
 Page size 
Unknown637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
Not available
S-EPMC7777904 | biostudies-literature
Unknown982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
Not available
S-EPMC8643917 | biostudies-literature
Unknown1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
Not available
S-EPMC7776548 | biostudies-literature
Sort   by:  
 Page size